Search ResultsShowing Results for 'Jean-Frederic Colombel'
Jean-Frederic Colombel, ECCO 2023: A sub-analysis investigating upadacitinib for rapid symptom relief in Crohn’s disease
The U-EXCEL (NCT03345849) and U-EXCEED (NCT03345836) phase 3 studies investigated the efficacy and safety of upadacitinib, an oral, selective JAK inhibitor in patients with moderate-to-severe Crohn’s disease. touchIMMUNOLOGY were delighted to speak with Dr. Jean-Frederic Colombel (Icahn School of Medicine, Mount Sinai, New York, NY, USA) to discuss his sub-analysis of the data from U-EXCEL […]
Jean-Frederic Colombel, ECCO 2023: LIBERTY-CD: subcutaneous infliximab as Crohn’s disease maintenance therapy
LIBERTY-CD (ClinicalTrials.gov Identifier: NCT03945019) is a phase 3 study investigating the efficacy and safety of subcutaneous infliximab as maintenance therapy in moderately to severely active Crohn’s disease. In this touchIMMUNOLOGY interview we spoke with Dr. Jean-Frederic Colombel (Icahn School of Medicine, Mount Sinai, New York, NY, USA) to discuss the aims, methodology and findings from […]
Jean-Frederic Colombel, CCC 2021: Overcoming the Plateau in IBD Treatment
We were delighted to speak with Jean-Frederic Colombel (Icahn School of Medicine at Mount Sinai, New York, US) around his talk on ‘Overcoming the Plateau in IBD Treatment’ which was presented at the virtual 2021 Crohn’s & Colitis Congress, 21-24 January, 2021. Questions Could you tell us about the plateau in drug efficacy that occurs […]
Jean-Frederic Colombel, ECCO-IBD 2022: Upadacitinib in Ulcerative Colitis: Results from the UPA Phase 3 Programme
touchIMMUNOLOGY caught up with Professor Jean-Frederic Colombel (The Mount Sinai Hospital, NY, USA) to discuss the results from the UPA phase 3 programme, investigating the efficacy of upadacitinib on the extraintestinal manifestations of ulcerative colitis. The abstract entitled ‘Effect of upadacitinib (UPA) treatment on extraintestinal manifestations (EIMs) in patients with moderate-to-severe Ulcerative Colitis (UC): Results […]
Jean-Frederic Colombel, DDW 2022: U-EXCEED Phase 3 Study – Upadacitinib for Moderate to Severe Crohn’s Disease
touchIMMUNOLOGY caught up with Prof. Jean-Frederic Colombel (Icahn School of Medicine, Mount Sinai, New York, NY, USA) to discuss the objectives, design and findings from the U-EXCEED phase 3 study, investigating upadacitinib induction therapy in moderate to severe crohn’s disease. The abstract ‘EFFICACY AND SAFETY OF UPADACITINIB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY […]
Platelet Rich Plasma therapy for tendinopathies: Jean-François Kaux, WCO-IOF-ESCEO 2023
Platelet Rich Plasma (PRP) therapy uses growth factors and cytokines in platelets to repair damaged cartilage, tendons, ligaments, muscle and bone. touchIMMUNOLOGY were delighted to speak with Professor Jean-François Kaux (University of Liège, Liège, Belgium) to discuss the clinical evidence supporting the use of PRP in tendinopathies, where PRP fits into the treatment paradigm and […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!